Saad Usmani to Cost-Benefit Analysis
This is a "connection" page, showing publications Saad Usmani has written about Cost-Benefit Analysis.
Connection Strength
0.389
-
Hansen DK, Lu X, Puglianini OC, Sorensen S, Usmani SZ, Zhang E, Huo S, Zhang Y, Qureshi ZP, Jagannath S. Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. Front Immunol. 2024; 15:1408892.
Score: 0.193
-
Hamadeh IS, Reese ES, Arnall JR, Kachur E, Martin AL, Schneider M, Friend R, Paul B, Atrash S, Bhutani M, Voorhees PM, Usmani SZ. Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol. Clin Lymphoma Myeloma Leuk. 2020 08; 20(8):526-532.e1.
Score: 0.142
-
Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, Perciavalle M, De Wiest D, Huo S, Lee S, Qureshi ZP, Jagannath S. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar; 26(3):369-378.
Score: 0.054